Cannabix Technologies To Exhibit At National Safety Council (NSC) Safety Congress And Expo, Denver Colorado

(MENAFN- GlobeNewsWire - Nasdaq) VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the“Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its participation in the NSC Safety Congress & Expo, taking place September 15–17, 2025 in Denver, Colorado. The NSC Safety Congress & Expo is the world's largest annual event dedicated to workplace safety, health, and environmental professionals and will have thousands of attendees from over 70 countries. Cannabix will be exhibiting with distribution partner Alco Prevention Canada.

The event will provide a premier destination for marketing the Company's innovative breath testing hardware including its Cannabix Marijuana Breath Test (“MBT”) technology (Figure 1) and BreathLogix alcohol screening devices (Figure 2).

The MBT is focused on“recent use” detection of delta-9 THC. The MBT hardware includes Cannabix's proprietary Breath Collection Unit (BCU) and Breath Cartridges (BC) technology which are designed to collect and preserve breath samples to be analysed with gold standard LC-MS methods to detect delta-9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis.

Figure 1. Sample Collection with Cannabix Breath Collection Unit

The BreathLogix unmanned alcohol screening devices rapidly check for breath alcohol and simultaneously takes a photo of the user to confirm and record identity (Figure 2 and 3). The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated 'Connect' web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.

In May, the Company's BreathLogix“Workplace Series” device was approved by National Highway Traffic Safety Association (in the United States) to be added to the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screen devices.

Figure 2. BreathLogix Alcohol Screening Devices

Figure 3. BreathLogix Alcohol device available with contactless and straw modes for rapid workplace pre-access alcohol screening

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at ... .

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company's development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any“patent pending” or“provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos accompanying this announcement are available at:

MENAFN08092025004107003653ID1110031084